Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
This study aims at developing, implementing and evaluating a complex intervention involving Learning, Innovation, Volunteers and Empowerment for home dwelling persons with dementia and their caregivers. The investigators hypothesise that a successfully implemented intervention will reduce caregivers burden and be cost-effective.
Description: RUD:A validated tool for assessment of time use for cost effectiveness analyses, measuring total time use in hours/day for different activities, numbers of contact points with care professionals and use of medications, high time use, many contacts and many medications indicates high resource use
Measure: Resource Utilization in Dementia Time: up to 24 months follow up, assesment every 6 monthsDescription: RSS: measuring caregiver distress, 15 items ranging from 0-4, high score indicates high burden
Measure: Relative stress scale Time: up to 24 months follow up, assessment every 6 monthsDescription: I-ADL scale assessing instrumental activities such as use of telephone, economy, household, public transport and shopping, range from 8-31, higher score indicates poorer functioning
Measure: Activities of daily living, instrumental Time: 24 months follow up, assesment every 6 monthsDescription: CSDD: Cornell scale for depression in dementia, range 0-38, high score indicates high symptom load
Measure: Depression and mood Time: 24 months follow up, assesment every 6 monthsDescription: CMAI: Cohen-Mansfield Agitation Inventory, 29 items assessing the frequency of agitated behaviour, range 29-203, high score indicates higher severity
Measure: Agitation Time: 24 months follow up, assesment every 6 monthsDescription: NPI: presence, severity and burden of depression, anxiety, psychosis and motor disturbances, range from 0-144, high score indicates frequent, severe and burdensome symptoms
Measure: Neuropsychiatric symptoms Time: 24 months follow up, assesment every 6 monthsDescription: Falls, disappearances outdoor, admissions to acute wards, fire hazard
Measure: Adverse events Time: 24 months follow up, assesment every 6 monthsDescription: number of technical aids, cognitive intervention devices and assisted-living systems
Measure: Use of assistive technology Time: 24 months follow up, assesment every 6 monthsDescription: number of participants with contact with a volunteer, number of hours spent with volunteer
Measure: Use of volunteers Time: 24 months follow up, assesment every 6 monthsDescription: P-ADL, assessing personal activities such as toileting, grooming, dressing, transfer and eating, scale range 6-30, higher score indicates poorer personal functioning
Measure: Activities of daily living, personal Time: 24 months follow up, assesment every 6 monthsDescription: EQ-5D-5L, Descriptive measure of health related quality of life comprising 5 Dimensions With 5 Levels each, scores can be converted to a single summary index number
Measure: Quality of Life Time: 24 months follow up, assesment every 6 monthsDescription: EQ-5D, Descriptive measure of quality of life rated on a VAS scale range 0-100, high score indicates good health
Measure: Quality of Life VAS scale Time: 24 months follow up, assesment every 6 monthsDescription: QoL-AD: Quality of life in Alzheimer dementia, 13 items likert scale, range from 13-52 points, high score indicates high quality of life
Measure: Quality of Life Time: 24 months follow up, assesment every 6 monthsDescription: number of hours spent with a volunteer
Measure: Use of volunteers Time: 24 months follow up, assesment every 6 monthsDescription: Clinical global impression of change, to quantify and track patient progress and treatment response on a scale from 1 to 7, at which 7 indicates substantial worsening.
Measure: Change achieving Time: at the start of intervention, and every 6 monthsDescription: GDS: Geriatric depression scale, 30 items rated yeas or no, high score indicates high burden
Measure: Caregiver depression Time: 24 months follow up, assesment every 6 monthsDescription: GMHR: General medical health rating scale, 4 point likert scale, range from 1-4, high score indicates high comorbidity burden
Measure: Comorbidity Time: 24 months follow up, assesment every 6 monthsDescription: MOBID-2: assesses the intensity of pain based on interpretation of pain related behaviour, range from 0-10, high score indicates high pain intensity
Measure: Pain in dementia Time: 24 months follow up, assesment every 6 monthsDescription: IQ CODE: Proxy rater instrument for assessment of change in cognitive performance the last 10 years, range 16-80, high score indicates great decline
Measure: Change in cognitive performance Time: BaselineDescription: Self and proxy reported use of medications, both regular and on demand
Measure: Medication use Time: At the start of the intervention, and every 6 onth follow upDescription: Participation in educational programes, both for persons with dementia and for caregivers.
Measure: Participation in educational programs Time: 24 months follow up, assessment every 6 monthsDescription: Caregivers perception of risk of contamination With Sars-Cov-10
Measure: COVID-19: risk perception Time: month 6 to month 12 (during COVID-19 lock down in Norway)Description: Change in services and contact due to restrictions of COVID-19
Measure: COVID-19: restrictions Time: month 6 to month 12 (during COVID-19 lock down in Norway)Description: Caregivers perception of caregiver burden during COVID-19
Measure: COVID-19: caregiver burden Time: month 6 to month 12 (during COVID-19 lock down in Norway)Description: NPI: change in presence, severity and burden of depression, anxiety, psychosis and motor disturbances
Measure: COVID-19: neuropsychiatric symptoms Time: month 6 to month 12 (during COVID-19 lock down in Norway)Description: CSDD: Change in cornell scale for depression in dementia.
Measure: COVID-19: depression and mood Time: month 6 to month 12 (during COVID-19 lock down in Norway)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports